Can You Take Wegovy While Pregnant? Why the Obesity Indication Changes the Conversation

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Key Takeaways

• Wegovy is contraindicated in pregnancy per FDA labeling. Discontinue when pregnancy is recognized.
• Wegovy and Ozempic share an active ingredient (semaglutide) but differ in indication: Wegovy is approved for chronic weight management; weight loss is not a clinical goal during pregnancy.
• Pre-pregnancy discontinuation should occur at least 2 months before conception attempts.
• Inadvertent first-trimester exposure prompts standard obstetric counseling, a detailed anatomy ultrasound, and consideration of pregnancy registry enrollment.
• Postpartum restart depends on breastfeeding plans; LactMed advises against use during nursing.

Direct answer

Wegovy is not recommended in pregnancy. The FDA label contraindicates its use because weight loss is not a clinical goal during pregnancy and semaglutide carries animal reproductive toxicity signals. Discontinue when pregnancy is recognized and ideally 2 months before planned conception. If you are pregnant, planning pregnancy, or breastfeeding, do not start, continue, or stop GLP-1 medications without OB-GYN sign-off.

Table of contents

1. What the Wegovy label says about pregnancy
2. The contraindication versus warning distinction
3. Same drug, different indication: why this matters
4. The shared animal data
5. Pre-pregnancy planning specific to Wegovy patients
6. Gestational weight gain after Wegovy discontinuation
7. If you become pregnant on Wegovy
8. The role of ACOG and Endocrine Society guidance
9. Postpartum and breastfeeding considerations
10. The contrary view: bariatric outcomes
11. FAQ
12. Sources

What the Wegovy label says about pregnancy

The Wegovy prescribing information includes a contraindication in pregnancy. The label states that Wegovy is contraindicated in pregnancy because weight loss offers no potential benefit to a pregnant patient and may result in fetal harm. The instruction is to discontinue Wegovy when pregnancy is recognized.

This is stronger language than the Ozempic label, which uses "not recommended" and "discontinue when pregnancy is recognized" but does not list pregnancy as a contraindication. The distinction reflects the difference in indication.

The contraindication versus warning distinction

FDA labeling has a hierarchy: contraindications, warnings, precautions, and use in specific populations. A contraindication means a clinical situation in which the drug should not be used because the risk clearly outweighs any benefit. A warning is a serious adverse event signal that requires attention but does not bar use.

Wegovy in pregnancy is in the contraindication tier because there is no obstetric scenario in which weight loss is a treatment goal. The risk-benefit balance is clearly tilted; no benefit exists to weigh against potential harm. The label language reflects this.

Same drug, different indication: why this matters

Wegovy and Ozempic are both semaglutide. The active ingredient is identical. Wegovy uses higher maximum doses (up to 2.4 mg weekly versus up to 2 mg for Ozempic). The pharmacology is the same; the indication is different.

For a pregnant patient with type 2 diabetes who had been on Ozempic, the question is how to manage diabetes during pregnancy. Insulin is the answer. The transition has clinical content.

For a pregnant patient who had been on Wegovy for obesity, the question is how to manage weight gain during pregnancy. The answer is appropriate gestational weight gain through nutrition and activity. The transition is mostly about discontinuing one approach and not replacing it with another medication.

The shared animal data

Because Wegovy and Ozempic share an active ingredient, the animal reproductive toxicity data are the same:

• Rat: embryofetal mortality, structural abnormalities, growth alterations at clinically relevant exposures.
• Rabbit: pregnancy losses and structural abnormalities at exposures below the maximum recommended human dose.
• Cynomolgus monkey: pregnancy losses and structural abnormalities at exposures comparable to human therapeutic doses.

The monkey data are particularly relevant because exposures sat near human therapeutic levels. These findings are the toxicologic basis for the pregnancy warnings on all semaglutide products.

Pre-pregnancy planning specific to Wegovy patients

Patients taking Wegovy who plan to conceive face a specific planning question: how to maintain or extend weight loss benefits while transitioning off medication in time for conception.

Practical components:

• Discontinuation at least 2 months before active conception attempts.
• Pre-pregnancy weight goals: stabilize at the lowest sustainable weight before discontinuation rather than peak weight loss.
• Nutrition and activity routines that can sustain weight without the medication.
• Treatment of obesity-related comorbidities (sleep apnea, hypertension, prediabetes) before conception.
• Mental health support if applicable; weight rebound after discontinuation can be psychologically difficult.

Gestational weight gain after Wegovy discontinuation

The Institute of Medicine ranges for gestational weight gain remain the standard:

Pre-pregnancy BMI	Recommended weight gain (singleton)
Underweight (less than 18.5)	28 to 40 lb
Normal (18.5 to 24.9)	25 to 35 lb
Overweight (25 to 29.9)	15 to 25 lb
Obese (30 and above)	11 to 20 lb

Some clinicians use lower targets for class II or III obesity. The goal is appropriate gain, not weight loss. Patients who had been on Wegovy may regain more than the IOM range without active management, which is part of why pre-pregnancy stabilization matters.

If you become pregnant on Wegovy

Inadvertent first-trimester exposure happens. The steps:

1. Stop the medication. Do not take additional doses.
2. Contact your prescriber and book an OB-GYN intake visit within the week.
3. Begin a prenatal vitamin with at least 400 mcg folic acid.
4. Plan for a dating ultrasound and standard pregnancy intake labs.
5. Consider a maternal-fetal medicine consultation for exposure counseling.
6. Plan a detailed anatomy ultrasound at 18 to 22 weeks.
7. Enroll in the Novo Nordisk semaglutide pregnancy exposure registry if you are comfortable.

The role of ACOG and Endocrine Society guidance

ACOG Committee Opinion 731 (Obesity in Pregnancy) and Practice Bulletin 230 emphasize lifestyle approaches and management of obesity-related comorbidities during pregnancy. Neither endorses pharmacologic weight loss during pregnancy.

The Endocrine Society's Clinical Practice Guideline on Pharmacological Management of Obesity recommends against the use of weight-loss medications during pregnancy and breastfeeding. The guideline aligns with FDA labeling and adds clinical context for obesity medicine specialists.

Postpartum and breastfeeding considerations

The question of restarting Wegovy after delivery depends on feeding plans. LactMed advises against semaglutide during breastfeeding until more data are available. Patients who plan to breastfeed exclusively typically defer restart until weaning or transition to combination feeding. Patients who are not breastfeeding can restart after discussion with their prescriber.

Postpartum weight retention is a common concern. Most clinicians recommend gradual weight loss through nutrition and activity during breastfeeding, with medication options reconsidered once feeding is stable or has ended.

The contrary view: bariatric outcomes

Some specialists in obesity medicine and maternal-fetal medicine note that severe untreated obesity has documented teratogenic and obstetric risks (neural tube defects, gestational diabetes, preeclampsia, cesarean delivery, stillbirth). The argument: if discontinuing a weight-management medication results in worse maternal weight at conception, the net teratogenic risk may not decrease.

This view does not justify continued use of Wegovy during pregnancy. It informs the importance of pre-pregnancy weight optimization, often through Wegovy or bariatric surgery, with a planned discontinuation that maintains weight benefits into the conception window.

The cleaner framing: Wegovy can be part of pre-pregnancy preparation. It is not part of pregnancy care.

Compounded medication note for this topic

For Can You Take Wegovy While Pregnant? Why the Obesity Indication Changes the Conversation, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.

The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.

What to verify before using this answer

The useful next step for Can You Take Wegovy While Pregnant? Why the Obesity Indication Changes the Conversation is to verify the details that can change the decision: current labeling, insurance rules, pharmacy instructions, dose timing, contraindications, and whether the evidence applies to your diagnosis rather than only to weight loss headlines.

For this women's health page, the most relevant search terms are can, you, take, wegovy, while, pregnant. Those terms point to a practical decision, so the answer should be checked against a current prescription label, payer policy, trial result, or clinician recommendation before you act.

FormBlends keeps this page focused on patient-level decision points: what is known, what is uncertain, what should be handled by a licensed clinician, and what should be avoided because it creates dosing, safety, or access risk.

FAQ

Can you take Wegovy while pregnant?

No. The FDA label contraindicates use in pregnancy.

Why is Wegovy specifically called out as contraindicated?

Weight loss is not a clinical goal during pregnancy. The risk-benefit balance has no benefit to weigh against potential harm.

How is Wegovy different from Ozempic in pregnancy guidance?

Same active ingredient at higher doses. Different indication. Wegovy gets stronger label language because the obesity indication offers no pregnancy-justified continuation.

How long before pregnancy should I stop Wegovy?

At least 2 months.

What do I do if I become pregnant on Wegovy?

Stop, call your prescriber and OB-GYN, begin prenatal vitamins.

Will my weight rebound during pregnancy?

Some regain is common. Gestational weight gain follows IOM ranges.

What about gestational weight gain targets?

11 to 20 lb for obesity, 15 to 25 lb for overweight, 25 to 35 lb for normal weight (singleton).

What does ACOG say about obesity medications in pregnancy?

Does not endorse pharmacologic weight loss during pregnancy.

Can Wegovy help me prepare for pregnancy?

Yes, as pre-pregnancy weight optimization with planned discontinuation 2 months before conception attempts.

Is breastfeeding an issue after Wegovy?

Yes. LactMed advises against use during nursing.

Related guides

• Can You Take Mounjaro While Pregnant? The Tirzepatide Diabetes Indication and Pregnancy Pathway
• Can You Take Ozempic While Pregnant? What the FDA Label, Animal Studies, and ACOG Actually Say
• Can You Take Zepbound While Pregnant? Tirzepatide-Specific Considerations and Pre-Conception Planning
• Can You Take Ozempic While Breastfeeding? The LactMed Position, Manufacturer Guidance, and What Clinicians Actually Do
• Can You Take Peptides While Breastfeeding?

Sources

1. FDA. Wegovy (semaglutide) injection prescribing information. Contraindications and Use in Specific Populations.
2. FDA. Ozempic (semaglutide) injection prescribing information.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
4. American College of Obstetricians and Gynecologists. Practice Bulletin 230: Obesity in Pregnancy. 2021.
5. American College of Obstetricians and Gynecologists. Committee Opinion 731: Obesity in Pregnancy. 2018, reaffirmed.
6. Institute of Medicine. Weight Gain During Pregnancy: Reexamining the Guidelines. 2009.
7. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. JCEM. 2015 with updates through 2024.
8. Novo Nordisk. Semaglutide Pregnancy Exposure Registry.
9. National Library of Medicine. LactMed. Semaglutide entry.
10. European Medicines Agency. Wegovy Summary of Product Characteristics. Section 4.3 and 4.6.
11. Society for Maternal-Fetal Medicine. Consult Series on Pregnancy Care for Patients with Obesity.
12. Briggs Drugs in Pregnancy and Lactation. Most recent edition.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with independent licensed clinicians and U.S.-based pharmacies. We do not prescribe or dispense medication directly. Obstetric decisions belong to you and your OB-GYN.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved. Pregnancy contraindication that applies to Wegovy applies with at least equal weight to compounded semaglutide formulations prescribed for weight loss.

Results Disclaimer. Pregnancy and gestational weight gain outcomes vary by individual. This article describes general clinical context; your obstetric provider will personalize recommendations.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.